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ABSTRACT
Enterovirus B species typically cause a rapid cytolytic infection leading to efficient release of progeny
viruses. However, they are also capable of persistent infections in tissues, which are suggested to
contribute to severe chronic states such as myocardial inflammation and type 1 diabetes. In order
to understand the factors contributing to differential infection strategies, we constructed a chimera
by combining the capsid proteins from a fast cytolysis causing echovirus 1 (EV1) with non-structural
proteins from Coxsackievirus B5 (CVB5) showing persistent infection in RD cells. The results showed
that the chimera behaved similar to the parental EV1 leading to efficient cytolysis in both permissive
A549  and  semi-permissive  RD  cells.  In  contrast  to  EV1  and  chimera,  CVB5  replicated  slower  in
permissive cells and showed persistent infection in semi-permissive cells. However, there was no
difference in the efficiency of uptake of CVB5 in A549 or RD cells in comparison to the chimera or
EV1. CVB5 virus batches constantly contained significant amounts of empty capsids, also in
comparison to its close relative CVB3. During successive passaging of batch containing only intact
CVB5, increasing amounts of empty and decreasing amounts of infective capsids were produced.
Our results demonstrate that the increased amounts of empty particles and lowering amounts of
infective particles is dictated by the CVB5 structural proteins leading to slowing down the infection
between passages. Furthermore, the key factor for persistent infection is the low amount of
infective particles produced, not the high number of empty particles accumulating.
This is the accepted manuscript of the article, which has been published in Journal of Virology. 2019, 
93(20), e01130-19. https://doi.org/10.1128/JVI.01130-19
IMPORTANCE
Enteroviruses cause several severe diseases with lytic infections that lead to rapid cell death but
also persistent infections that are more silent, and lead to chronic states. Our study compared a
cytolytic echovirus 1 infection to persistent coxsackievirus B5 infection by making a chimera
between the structural proteins of echovirus 1 and non-structural proteins of coxsackievirus B5.
Coxsackievirus B5 infection was found to lead to production of high number of empty viruses (empty
capsids), that do not contain genetic material and are unable to continue the infection. Coinciding
with  high  number  of  empty  capsids,  also  the  amount  of  infective  virions  decreased.  This
characteristic property was not observed in the constructed chimeravirus, suggesting that structural
proteins are in charge of these phenomena. These results shed light on the mechanisms that may
cause persistent infections. Understanding events leading to efficient or inefficient infection are
essential in understanding the virus caused pathologies.
INTRODUCTION
Human enteroviruses are a large group of disease causing pathogens belonging to the family of
Picornaviridae. Enterovirus infections in man can result in different diseases, from mild flu-like
diseases to more severe symptoms such as meningitis, myocarditis and paralysis.
The icosahedral viral capsid is formed from four capsid proteins, VP1 to VP4. VP1, VP2 and VP3 are
partly exposed from the capsid while VP4 is an internal protein that becomes exposed during early
entry events and A-particle formation. The single-stranded enterovirus RNA genome of positive
polarity encodes for 11 proteins, seven non-structural and four structural proteins in a single open
reading frame. Both 3’ (ending with a poly A sequence) and 5’ ends of the genome have non-
translated regions which are functional in the replication process.
Enterovirus B species contain different serotypes and novel, only genetically characterized types,
including established and well characterized serotypes Coxsackieviruses B3 (CVB3), B5 (CVB5) and
echovirus-1 (EV1). All CVBs use CAR as a receptor for attachment and entry (1, 2) but CVB1, 3, 5 and
6 may also use the decay accelerating factor (DAF, CD55) for attachment at the cell surface (3, 4).
CAR is a tight junction localized transmembrane protein that can be used for entry into the cell (5,
6). The CVB/CAR interactions are associated with changes in the virion morphology resulting in A-
particle formation and the release of the viral genome. In CVB3 this phenomenon has been
suggested to start already during receptor binding and virus can internalize either with or without
the receptor, depending on the cell type (7-9). EV1, on the other hand, uses the collagen-binding
integrin α2β1, which is abundantly expressed in many cell types. EV1 internalizes together with its
receptor and introduces a novel entry pathway, distinct from the natural pathway for the integrin
receptors. In contrast to CVB interactions with CAR, EV1 binding to its integrin does not lead to
uncoating but rather, uncoating takes place in non-acidic multivesicular structures and the viral
genome is then released into the cytoplasm (10-12).
First signs of cell death can be seen after 4h p.i. leading to cell death within 8h p.i. depending on the
virus and host cell (14). Most often the infections lead to cytolysis in cell cultures but enteroviruses
may also cause persistent infections (15-19). Persistent infections have been suggested to cause
chronic states leading to serious consequences, such as promoting the onset of type I diabetes in
the pancreas tissue (20). Therefore, it is important to understand the detailed mechanisms behind
switching between cytolytic and persistent infections. Enteroviruses have several mechanisms to
cause the host cell death and, similarly, the host cell has several mechanisms to combat the virus
infection and cell death (21). The interplay between host and the virus defines the outcome of the
infection. Viral non-structural proteins act via inducing the host-cell shut-down, inhibiting cap-
dependent translation and activating caspases. Viral structural proteins VP1, VP2 and VP3 have also
been shown to have cause apoptosis, either by caspase activation or by cleavage of the poly-ADP
ribose polymerase (PARP) (14).
In this study, a chimera between EV1 and CVB5 was constructed using reverse genetics and to study
the role of non-structural and capsid proteins in the infection kinetics. The results show that the P1
region, contrary to P2 and P3, determines the efficiency and outcome of an infection. In this
experimental model, the P1 region, encoding the CVB5 structural proteins, contain specific
characteristics that lead to low amounts of intact virions and high incidence of empty capsids, which
then slowed down the progression and kinetics of the secondary infection. We further show that
the empty particles themselves did not inhibit cell binding or infection but the actual number of
infective particles had a direct effect on infection kinetics.
MATERIALS AND METHODS
Cells. Virus productions and infectivity determinations were done in green monkey kidney cells
(GMK) and cell experiments were carried out in human rhabdomycosarcoma (RD) and human lung
carcinoma  cells  (A549).  All  cell  lines  were  obtained  from  the  American  Type  Culture  Collection
(ATCC) and maintained in either Eagle’s Minimum Essential Medium  (MEM) or Dulbecco's Modified
Eagle Medium (D-MEM, Gibco Life Technologies) containing 5 to 10 % of fetal bovine serum (FBS),
GlutaMAX, and penicillin-streptomycin antibiotics which were obtained from Gibco, Life
Technologies.
Antibodies and reagents. The following primary antibodies were used in the experiments:
monoclonal anti dsRNA antibody (J2; English & Scientific Consulting Kft.), rabbit polyclonal antibody
against EV1 (12), anti CVB5 (DAKO; Monoclonal Mouse, Anti-Enterovirus Clone 5-D8/1), CVB3
capsids  were  detected  with  CVA9  targeted  rabbit  polyclonal  antibody  (kind  gift  from  Merja
Roivainen, THL, Helsinki). Fluorescently conjugated goat secondary antibodies were purchased from
Molecular Probes, Invitrogen.
Cloning of chimera construct. The origin of the CVB5 strain Dalldorf (CVB5D) and its infectious cDNA
clone have been described elsewhere (22-24). This virus was used by Reagan et al. for adaptation to
cytolytic infection in RD cells by massive MOI (multiplicity of infection). Normal MOI results in a
persistent infection of RD cells (24). Previously a recombinant variant of the infectious cDNA clone
was used to generate an ancestor for the circulating CVB5 strains in the world and as an efficient
recombinant  infectious  cDNA  clone  where  the  P1  regions  was  replaced  by  other  enterovirus  B
structural genes (24, 25) and upon transfection resulted in replicating chimera viruses. A plasmid,
pCR Script SK+, was constructed using the infectious cDNA clone of CVB5 where the complete
genome was derived from the CVB5 genome sequence and unique restriction enzyme recognition
sites where introduced enabling replacement cloning of the P1 region as previously described (26).
The P1 region comprised of EV 1 (Farouk strain) P1 sequence thus coding for EV1 VP1-VP4 structural
proteins and the remaining part of the genome was derived from the CVB5 genome (EV1/CVB5cDNA
aka chimera). A pSPORT plasmid was provided for positive control experiments. This cDNA clone
contains a complete EV1 genome including the P1, P2, and P3 sequence coding for the EV1 structural
genes and corresponding NSPs (kind gift from Jeff Bergelson). The plasmids were amplified using
ampicillin selection in DH5 cells and purified using Qiagen mini-prep kit.  Plasmid size and correct
insertion was confirmed with restriction enzyme digestion and gel electrophoresis. GMK cells were
transfected with EV1cDNA and chimera using a Lipofectamine protocols, changing media after 6hr
incubation at 37C. Transfected cells were passaged until GMK cells were observed to cause cytolysis.
Cells were collected, freeze thawed three times cell debris was pelleted down.  Supernatants were
used for crude virus infection of fresh GMK cells following virus purification.
Virus stock production. After successful transfection of the plasmids and production of the crude
virus extracts, GMK cells were infected with the crude virus stocks of EV1, chimera, CVB3 (Nancy
strain from ATCC) and CVB5 for 24 h in 5-layer bottles, after which the cells were collected and lysed
via three freeze-thaw cycles. Viruses were purified as described earlier (27). Sucrose gradient 5 -
20% was used for CVB3 and CVB5 and fractions from 12 to 21 were collected. A separate batch of
CVB5 was purified using 5-20% sucrose gradient but only fractions from 14 to 21 were collected to
avoid empty particles. Also, empty capsids from fractions 8-11 were collected separately. For EV1
and chimera sucrose gradient of 10-40 % were used and three fractions on basis of the A260 nm
spectrophotometric data were collected. Finally, collected virus fractions were concentrated using
ultracentrifugation. Virus infectivity was assessed by end-point dilution and concentration of the
virus stock was determined by the measurement of absorbance at A260 nm.
Cell viability assay. Cell viability was determined with the aid of Cell Titer Glo –kit (promega). Briefly,
substrate was added straight to cell media avoiding the possible loss of loosely attached cells. Two
to three independent experiments with at least three replicate samples were performed in each
case.
Production of radioactively labelled of EV1, Chimera and CVB5. GMK or A549 cells were cultured
until sub-confluency in MEM or D-MEM supplemented with 10% FBS, 1% Glutamax and 1%
penicillin/streptomycin antibiotics. Cells were infected with EV1, chimera and CVB5 in low
methionine/cysteine medium supplemented with 1% dialyzed FBS and 1% Glutamax. The infection
was allowed to proceed at + 37 ᵒC for 3 h, after which the medium was changed into fresh low
methionine/cysteine medium supplemented with 1% dialyzed FBS and 1% Glutamax containing 50
µCi/ml of radioactive Sulphur. The infection was allowed to proceed at + 37 ᵒC for another 15 h or
21 h so that the total infection time was 18 h or 24 h, respectively. The cells were freeze-thawed
three times, after which 100 mM Octyl β-D-glucopyranoside (Amresco) was added to isolate
membrane bound virus particles. Cell debris was centrifuged with a microcentrifuge 5415 D
(Eppendorf) at 16,000 rpm for 5 min. Supernatant was collected and added on top of 5-20% linear
sucrose gradients. The gradients were collected from the top into 500 µl fractions. An aliquot from
each fraction was added with scintillation cocktail (Ultima Gold MV, Perkin Elmer) and the CPM of
each fraction was measured with liquid scintillation analyzer (Tri-Carb 2910 TR, Perkin Elmer). The
fraction CPM was normalized to the sum of the total CPM of the whole gradient.
Immunolabeling and microscopy. An immunolabeling experiment was carried out in cells grown on
coverslips. Cells were fixed with 4% PFA for 20 min at RT. The cells were permeabilized with 0.2%
Triton X-100 and then treated with primary antibodies. After primary antibody incubation the cells
were washed extensively with PBS. Appropriate secondary was added to cells at RT and incubated
for 30 min and finally, the cells were extensively washed with PBS and mounted with Prolong gold
antifade reagent supplemented with 4=,6-diamidino-2- phenylindole (DAPI) (Molecular Probes, Life
Technologies).  Immunolabeled  samples  were  imaged  with  an  Olympus  IX81  microscope  with  a
FluoView-1000 confocal setup. In total, 400 to 600 cells were imaged to manually quantify the
percentage of replication and capsid positive cells.
Gel electrophoresis. The protein compositions of the virus stocks were analyzed by using a 4 to 12%
NuPAGE Bis-Tris gel (Novex, Life Technologies). The proteins were denatured with the gel sample
buffer provided by the manufacturer (NuPAGE; Life Technologies) at 100°C before they were loaded
onto the gel. The gel was stained with commassie stain including fixative.
Passage assay. A549 cells were cultured on 96-well plates close to confluency in D-MEM
supplemented with 10% FBS, 1% Glutamax and 1% penicillin/streptomycin antibiotics. Cells were
infected with MOI 500 of EV1, chimera, CVB5 and CVB3 and the viruses were diluted in D-MEM
supplemented with 1% FBS and 1% glutamax. The infection was allowed to proceed at +37 ᵒC for 2
h, after which the medium was changed into fresh D-MEM supplemented with 10% FBS and 1%
glutamax. The infection was then allowed to proceed at +37 ᵒC for another 16 h. Next, half of the
culture medium was passaged to new A549 cells and infection was allowed to proceed at +37 ᵒC for
2 h, after which the medium was changed. The infection was then again allowed to proceed for 16
h at +37 ᵒC. After passaging, the cells were always stained with crystal violet containing stain (8.3
mM crystal violet, 45 mM CaCl2, 10% ethanol, 18.5% formaline, and 35 mM Tris-Base) for 10 min,
after which excess stain was washed with water. Finally, lysis buffer (47.5% EtOH; 35 mM sodium
citrate; 12.5 mM HCl) was added to dissolve the stained cells and the absorbance was measured at
570 nm with a Victor X4 2030 multilabel reader (PerkinElmer).
Infection in the presence of empty capsids. A549 cells were cultured on 96-well plate in D-MEM
supplemented with 10% FBS, 1% glutamax and 1% penicillin/streptomycin antibiotics. Cells were
infected with the intact particles of CVB5 with MOI 0.7, 6.5, 21, 43 or 65 corresponding to 0.07, 0.65,
2.1, 4.3 and 6.5 ng, respectively. The virus mixture also contained different amounts of CVB5 empty
particles (1.5, 3, 6 or 9 ng). The infection was allowed to proceed in D-MEM supplemented with 1%
FBS, 1% glutamax and 1% penicillin/streptomycin antibiotics at +37 ᵒC for 20 h. Next, the cells were
stained with crystal violet containing stain (8.3 mM crystal violet, 45 mM CaCl2, 10% ethanol, 18.5%
formaline, and 35 mM Tris-Base) for 10 min, after which excess stain was washed with water. Finally,
lysis buffer (47.5% EtOH; 35 mM sodium citrate; 12.5 mM HCl) was added to dissolve the stained
cells and the absorbance was measured at 570 nm with a Victor X4 2030 multilabel reader
(PerkinElmer).
Titration using end point dilution assay. GMK cells were cultured on 96-well plate in MEM
supplemented with 10% FBS, 1% glutamax and 1% penicillin/streptomycin antibiotics. Cells were
infected with the purified viruses or supernatants derived from passage assay by preparing a dilution
series in MEM supplemented with 1% FBS and 1% GlutaMAX. The infection was allowed to proceed
at + 37 °C for three days, after which the cells were stained with crystal violet stain (8.3 mM crystal
violet, 45 mM CaCl2,  10%  ethanol,  18.5%  formalin,  and  35  mM  Tris  base).  The  excess  stain  was
washed with water, and the 50% tissue culture infective dose (TCID50) was calculated by comparing
the number of infected and uninfected wells for eight or four replicates of the same virus
concentration. The concentration at which half of the wells would be infected was extrapolated
(TCID50). Finally, the TCID50 value was multiplied by 0.7 to obtain the PFU/ml value.
RT-qPCR. A549 or RD cells were infected with EV1, chimera or CVB5 with MOI 10 in D-MEM
supplemented with 1% FBS and 1% glutamax. After 1 h, cells were washed with PBS, after which the
infection was allowed to proceed in D-MEM supplemented with 1% FBS and 1% glutamax for 2, 8,
24 or 48 h. At the end, the cells were freeze-thawed three times and cell debris was pelleted down
at full speed with table top centrifuge. Viral RNA from the supernatant was extracted according to
the instructions of the manufacturer using QiAmp viral RNA Mini Kit (Qiagen). Reverse transcription
was carried out for positive strand RNA using 1.2 µM antisense (5’-GAAACACGGACACCCAAAGTA)
primer, 20 U M-MLV reverse transcriptase (Promega), 4 U RNAsin ribonuclease inhibitor (Promega)
and dNTPs (Promega). The generated cDNA copy of the RNA was applied to qRT – PCR amplification
using the 7500 Real-Time PCR System (Applied Biosystems) with 7500 SDS analysis software. Each
reaction contained 5 ul template, 1 X Power SYBR Green Master Mix (Applied Biosystems) and 0.75
uM of antisense (5’-GAAACACGGACACCCAAAGTA) and sense (5’-CGGCCCCTGAATGCGGCTAA)
primers  for  a  final  volume  of  20  ul.  The  thermocycling  protocol  was  executed  as  follows:  pre  –
amplification step (involving denaturation and DNA polymerase activation) at 95 °C for 10 min.; 10
cycles of 15 s. at 95 °C, 30 s. at 64 °C – 55 °C (following a touch – down of 1 °C per cycle), and 40 s.
at 72 °C; 30 cycles of 15 s. at 95 °C, 30 s. at 55 °C, and 40 s. at 72 °C; and dissocation curve generation
for 1 cycle of 15 s. at 95 °C, 1 min. at 60 °C, and 15 s. at 95 °C. Each reaction was run in triplicate.
RESULTS
Enterovirus chimera containing the structural proteins of EV1 and non-structural proteins of CVB5
leads to an efficient replication and cytolysis in GMK and A549 cells, with infection kinetics
resembling EV1
By using a previously described backbone of the CVB5 genome infectious cDNA clone (Fig 1A),
replicating CVB5 and EV1/CVB5 viruses were generated. In addition, EV1 viruses were generated by
transfection of an infectious cDNA clone in GMK cells. EV1, CVB5 and the chimera viruses infected
GMK cells with a rather similar kinetics and cytolysis was typically seen after first 24 h of infection.
EV1 and chimera both lead to efficient production of progeny viruses showing high infectivity and
high protein concentration of 440 µg/ml and 870 µg/ml, respectively (Fig. 1B). CVB5 preparations
had  almost  two  logs  lower  measured  virus  titers  but,  in  contrast,  a  significantly  higher  protein
amount in comparison to the produced virus titers (pfu) (Fig 1B). Next, SDS-PAGE analysis of purified
virus  stocks  was  conducted  in  order  to  verify  the  purity  of  the  viruses  (Fig  1C).  Similar  protein
amounts of all the virus stocks showed two clear bands corresponding to sizes between 25-37 kDa
of approximately the same amount, indicating that all stocks were pure from major protein
contaminants and contained only the viral capsid proteins.
Virus infectivity and infection kinetics were then studied in more detail in both permissive A549 and
semi-permissive RD cell lines. A549 cells contain abundant amounts of the virus receptors CAR, DAF
and α2β1 integrins on their cell surface indicating these cells should be permissive for all three
viruses. RD cells on the other hand have been reported to have none or very limited CAR expression
with only subpopulations of cells expressing the CAR on their cell surface (28).
First, A549 cells were infected with equal protein amounts of virus stocks and cell viability was
measured at 12h and 24 h p.i. (Fig 1D). EV1 and chimera lead to rapid cytolysis: by 12h p.i. only half
of the cells were alive and at 24 h p.i. the complete cytolysis was observed. Cytolytic capacity of
CVB5 was notably slower, with 70 % of cells still viable at 24 h p.i. showing that cell destruction was
greatly delayed. However, at 72 h (data not shown), also CVB5 demonstrated complete cytolytic
efficiency. We then set out to compare cell viability after using similar number (virus titers) of
infective particles (Fig 1E). The results showed a similar trend as seen with infections with equal
protein amounts, suggesting that CVB5 infection kinetics was delayed when compared to EV1 and
chimera at 24 h p.i.
Since CVB5 is known to cause persistent infection in RD cells, our next aim was to characterize the
chimera infection in these cells as well. RD cells were infected first with equal protein amounts of
virus stocks and cell viability was determined at 12 h and 24 h p.i. The results showed that EV1 and
chimera were as cytolytic in RD cells as in A549 cells; around half of the cells had died at 12h p.i. and
almost entire cultures had been destroyed at 24 h p.i. (Fig 1F). On the contrary, at 24h, only one
third of CVB5 infected cells had lysed and even when the infection was continued until 48 h p.i., cell
viability remained the same (data not shown). Again, we performed another viability assay using
the same number of infective particles (Fig 1G). This experiment showed that not even high amounts
of infective virions were able to cause lytic CVB5 infection in RD cells. At 12 h there was slight
decrease in cell viability, but at 24 h CVB5 treated RD cells were as viable as the control. In contrast,
EV1 and chimera showed efficient cytolytic infection.
Altogether, the results suggested that the chimera, consisting of EV1 capsid proteins and CVB5 non-
structural proteins, was highly infective and cytolytic in both A549 and RD cells, in contrast to CVB5,
suggesting that the structural proteins are contributing to the switch to cytolytic infection.
CVB3 and CVB5 both show persistent carrier culture infection in RD cells whereas in permissive
A549 cells CVB5 has significantly slower infection kinetics
In order to study the possible role of the entry receptor, we included CVB3 in our studies as previous
studies has shown that both CVB3 and CVB5 use CAR and DAF. First, we monitored CVB3 and CVB5
infection in both A549 and RD cells. We monitored viability of cells that were infected with equal
MOI of viruses until 96 h p.i.. In A549 cells both viruses lead to the destruction of the entire cell
culture within 96 h confirming a lytic replication mode in permissive cells (Fig 2A). Although both
viruses demonstrated cytolytic replication of the cells in the end, CVB5 was notably slower than
CVB3. At 24 h p.i., almost all of the CVB3 infected cells had died, while around 60 % of the CVB5
infected cells were still viable. Infected RD cell cultures did not show apparent cell lysis with either
of the viruses (Fig 2C). Confocal microscopy confirmed the presence of viral capsid protein in
minority of the cells in the culture during the 96 h time series (data not shown), suggesting that both
viruses caused persistent infection in these cells. Even after 9 days of incubation with the viruses,
no significant cytotoxicity was observed for the cell culture (data not shown).  Since CVB5 infection
was notably slower in A549 when compared to CVB3 when using the same MOI, similar to what was
observed with EV1 and chimera (Fig 1B), we next studied in more detail the kinetics of capsid and
dsRNA  production.  We  infected  A549  and  RD  cells  with  equal  MOI,  fixed  the  cells  at  different
timepoints, immunolabelled against dsRNA and virus capsids and imaged with confocal microscopy.
After imaging, we quantified the images in order to determine the presence of capsid positive cells
(Fig 2B and D). In A549 cells, there was a clear difference in the percentage of dsRNA positive cells
when CVB3 and CVB5 infections were compared. At 6 h p.i, about 35 % of infected cells showed
positive label for dsRNA during CVB3 infections, whereas only 10% of CVB5 infected cells were
positive at same timepoint. However, at 12h both infections were showing equal amount of dsRNA
positive cells.  As the same experiment was performed with RD cells (Fig 2D), there was no major
difference in the number of cells showing infection between the two viruses for the first 48 h; viruses
could only replicate in a small subpopulation of cells. Cells infected with either of the virus showed
only around 10 % of the population that had newly synthetized capsid proteins present until 48 h
p.i.
To conclude, these results suggested that both, CVB3 and CVB5, eventually lead to cytolytic infection
in A549 cells and persistent infection of the RD cells but, importantly, CVB5 infection kinetics is
slower than CVB3.
CVB5 batches produced in GMK cells contain high-amounts of empty capsids
As CVB5 was notably slower in A549 cells, we started to compare the CVB3 and CVB5 virus stocks in
detail. First, as we compared the pfu/ml to mg/ml status of CVB3 and CVB5, we noticed a similar
phenomenon as when compared to EV1 and Chimera (Fig 1B): CVB5 contained more protein in
relation to its  pfu/ml when compared to CVB3 (Fig  3A).  For  more detailed understanding of  the
status of the viruses in purified batches, we performed transmission electron microscopy (TEM)
analysis of the virus stocks (Fig 3B). Negatively stained TEM samples showed that EV1 and chimera
mostly contained infectious virions (N-form), intact particles showing as light-coloured particles in
TEM images. Only a small percentage of empty, dark labeled particles were observed per frame. In
contrast, CVB5 batches had approximately 40 % of the virus particles with dark interior, suggesting
that the batch contained significant portion of empty capsids. This was an interesting finding and
possibly an explanation for differences observed during infection between these viruses.
Furthermore, when purified batches of CVB3 and CVB5 were compared, TEM analysis showed that
CVB5  batch consisted of only approximately 50 %  intact particles, whereas CVB3 batch contained
mostly intact particles (Fig 3B, bottom row). Altogether, these results showed that CVB5 batches
systematically contained high proportions of empty particles further explaining high virus protein
concentration vs infectivity readings.
Purified batch of CVB5 containing only intact particles leads to efficient infection
We then continued to further elucidate the role of the empty particles with CVB5 that only
contained complete virions, N particles. The intact viruses (160 S form of the virus) were separated
from  the  empty  virions  and  isolated  from  the  bottom  part  of  the  5-20%  sucrose  gradient.  TEM
analysis using negative staining confirmed that the new virus batch contained only intact virions (Fig
4A). Gradient fractionation of metabolically labeled viruses revealed no major differences between
the various viruses in GMK cells and suggested that all of them contained a majority of N particles
and a rather similar low amount of empty virions (Fig 4B). Similar results were obtained with A549
cells (Fig 4B). Also, cell viability measurement in A549 and RD cells after infection for 24 h, with the
same amount of intact virus, showed that CVB5 infection was almost as efficient in infection in
comparison to EV1, chimera and CVB3 in A549 cells and non-cytolytic in RD cells (Fig 4C). In order
to look at the replication kinetics in more detail, we decided to compare the amount of replication
using qPCR of the (+) strand RNA after using similar amount of infective particles from different
constructs in A549 cells. The results showed that the amount of virus load taken up during 2 h is
very similar between EV1 and chimera (Fig. 4D). Interestingly the, amount of CVB5 taken up during
2 h was even higher. There was no difference between the amounts of RNA produced after 8, 24 or
48 h. This result was replicated in an immunolabelling analysis detecting the replication
intermediate dsRNA and capsid by confocal microscopy (Fig 4E): EV1, chimera and CVB5 (intact)
showed ample amount of dsRNA and capsid in A549 cells.
qPCR evaluation of CVB5 replication in RD cells showed also that the uptake during 2 h to RD cells
was as efficient as with other constructs (Fig 4D). However, there was a clear difference after 8 h in
the amount of RNA produced: the amount of RNA was significantly lower, and the lower amounts
were also evident after 24 and 48 hours.
Generation of empty capsids during CVB5 replication is a characteristic trait that shows up during
serial passaging but do not explain the silencing of the infection
We then wanted to see how the infection would proceed within next generations when using the
CVB5 batch that only had intact particles. A549 cells were infected with equal MOIand the infection
efficiency  as  CPE  was  monitored  during  several  passages  until  passage  4  (Fig  5A).  Crystal  violet
staining of the passaged plates revealed that the first overnight infection by all viruses readily lifted
the cells from the wells indicative of good infection. However, when we dissolved the crystal violet
color and quantified the signal, the results showed that already during this first CPE, CVB5 showed
lower amount of detached cells in comparison to other viruses.  The next passages showed a much
clearer difference between CVB5 and other viruses, suggesting that almost all cells survived the
CVB5 infection. In contrast, there was no significant difference between EV1, chimera and CVB3, all
of them showing high CPE in all passages.
As the lower CPE for CVB5 could result either from higher number of empty or lower number of
infective particles, we measured the amounts of infectious virus particles produced in each step
from different constructs. The results showed that the EV1, chimera and CVB3 all had high amounts
of viruses in all passages although the actual pfu/ml varied in between 106 and 107 particles (Fig 6B).
Strikingly, quantification of the virions from CVB5 showed low pfu/ml of only 105 in the first passage,
and from there on the titers were too low to determine titer measurements. The titers for CVB5
kept under detection level during all consecutive passages suggesting that the infectivity dropped
very soon to a low level.
In order to study if the presence of empty particles could affect the CPE in A549 cells, we performed
two different experiments: 1) First we used a similar amount of intact CVB5 particles, on top of
which we added increasing amounts of empty particles. This approach showed that the increasing
amounts of empty capsids, the highest exceeding the number of intact virions by about 1.4 fold, did
not affect the infectivity of CVB5.  2) Next, we used increasing amounts of intact CVB5 virions on top
of  which  we  added  a  similar  and  high  amount  of  empty  particles  (Fig.  5C).  Also  this  approach
revealed only minor changes in cell viability, suggesting that at least the amounts of empty virions
used in the assay did not harm CVB5 infection efficiency.
Altogether, these results show that CVB5 batches have a tendency to produce lower amount of
intact particles and increased amounts of empty virus particles. The presence of empty capsids does
not affect infectivity, whereas the lowering amount of infective particles lead to slower infection
kinetics of permissive A549 cells.
DISCUSSION
Chimeric enteroviruses as an experimental approach has been an informative tool in studying
different enteroviral traits. Recently, a chimeric CVB3 strain with 5’ NTR of poliovirus was found to
lead  to  less  efficient  replication  than  the  parental  strain.  This  was  found  to  promote  immunity
against CVB3-mediated heart and pancreatic diseases, suggesting that chimeric viruses are useful in
vaccine research (29). Another study with chimeric constructs between respiratory (EV-D68) and an
enteric (EV-D94) EV, suggested that tropism was dictated by the capsid proteins, while innate
immunity was transferred via the NS-proteins, providing information on the roles of capsid and NS-
proteins (30). In general, the enterovirus type is determined by its P1 region. Due to high extent of
sequence conservation in the P2 and P3 regions, this part of the genome may be regarded as a
supportive and replicative backbone to the type determining P1 region. Recombination takes place
in the nature and e.g. different chimeric variants between endogenous viruses and vaccine strains
appear time to time (31).  Also, our results showed that viral structural elements between members
of the enterovirus B species are easily interchangeable within the EV-B group.
Our goal here was to see if chimeric enterovirus could reveal new information regarding the
mechanisms of persistent infections and the efficiency of lytic replication. We constructed a chimera
consisting of EV1 structural proteins and CVB5 non-structural proteins. These parental viruses were
selected for their known differences in their infection kinetics in cell culture. EV1 is a fast-acting
cytolytic virus, whereas CVB5 has been shown to lead to slower infection, when using the CVB5
strain and the cell types studied. The results altogether showed that the chimera was functional,
leading to fast cytolysis in A549 cells, highly resembling the EV1 infection kinetics. In contrast, CVB5
led to significantly slower onset of replication and CPE in A549 cells.
In cell cultures, enteroviruses usually cause lytic infections resulting in cell death from 6 h p.i.
onwards. One exception to this rule seem to be the human rhabdomyosarcoma cell line (RD), which
has been shown to result in persistent infection when infected with CVB2O (32), CVB3 (28) and CVB5
(16), whereas in Hela and A549 cells, these viruses cause cytolytic infection (data not shown). One
hypothesis for this phenomenon has been low or negligible transient expression of CAR in RD cells
(28). It is believed that the low CAR expression helps the virus to sustain a carrier culture persistency
in RD cell cultures as only subpopulation of the cells can get infected. Our data here supports this
hypothesis, as only subpopulation of the cells got infected and clear signs of cytotoxicity and
cytolysis was observed in those infected cells (data not shown), but the cell culture in general kept
viable. In addition to persistent infections, it seems that enteroviruses cultured in RD cells obtain
adaptations that lead to increased CPE within the culture, and eventually to total cytolysis of the
culture  (26,  33).  After  nine  passages  of  CVB2  Ohio-strain  (CVB2O)  in  RD  cells  Polacek  et  al  (32)
reported a phenotype of CVB2O that caused cytolysis of the culture. Both the parental and the
adapted strains lead to similar titers of cytolytic viruses in Hela cells, while parental strain was
showing decreased replication level in RD cells. Cytolytic trait was identified to be due to single
amino  acid  change  within  the  exposed  region  of  VP1  capsid  protein  (26),  suggesting  a  role  in
receptor  usage.  By  using  a  high  MOI,  it  was  however  possible  to  adapt  the  persistent  CVB2O
infection to a cytolytic one and the single mutation needed was a single mutation in VP1 (26). CVB3
has also been previously shown to adapt to RD cells by serial passaging causing increased CPE in
these cells. The obtained CVB3-RD strain had increased affinity to bind DAF in comparison to the
prototype strain CVB3-Nancy (23). This ability has been later mapped to two amino acid changes in
the VP2 capsid protein (34). Although both DAF and CAR mediate tight binding of the CVB3-RD
particle, only CAR supports the A-particle formation and internalization of the virus, while DAF most
likely has a sequestering role on the cell surface (35). In addition to receptor usage, even closely
related viruses can promote differential antiviral effects in their host cell. For example, two viruses
that are known to cause hand-foot-and-mouth disease (HFMD), EV71 and CVA16, lead to differential
activation of the interferon response in RD cells, further reflecting to their infection efficiency (36).
Our studies on EV1, chimera and CVB5, demonstrated that chimera had similar characteristics to
EV1 with respect to virus infection kinetics. Chimera showed efficient production of infective virus
particles, efficient replication as judged by qPCR and cytolysis with a similar time scale as with
parental  EV1.  As  CVB5  showed  negligible  cytolysis  in  RD  cells,  the  results  demonstrate  that  the
5´UTR or the non-structural P2-P3 part of the genome does not dictate the differences between the
chimera/EV1 and CVB5. Altogether these results suggested that the differences between CVB5 and
EV1/chimera rely on the structural proteins comprising the viral capsid. This led us to consider if
receptor binding and entry pathway could explain the marked difference between the constructs.
In order to compare CVB5 to another CVB with abilities to bind to same receptors, CAR and DAF, we
chose to use CVB3 in our experiments. Despite these similarities, there was still a clear difference
between these viruses, CVB3 being more cytolytic and efficient than CVB5 in permissive A549 cells,
suggesting that other factors than actual receptor binding would contribute to the slower lysing of
the cells during CVB5 infection. Furthermore, qPCR analysis of the uptake efficiency showed no
difference between the viruses. We therefore started to look for other differences between these
viruses.
The high number of empty virions in the CVB5 virus batches seemed to be the most apparent
difference between the two CVBVs. This was proven by TEM and by careful characterization of
protein and infective particle content of the preparations. Strikingly, the infection efficiency of the
CVB5 batch containing only intact and infective full viruses did not differ much between the viruses
during the first round of infection. The presence of empty capsid thus seemed to be a likely
explanation to the reduced efficiency of infection in subsequent passages.  However, detailed
analysis of the role of empty viruses, by adding various amounts of empty viruses on top of intact
virions showed clearly that the accumulation of empty virions does not interfere with infection using
the applied experimental set up. The results thus indicated that low amounts of intact viruses
produced and not the high amounts of empty viruses is the determining factor for the slowing down
of  infection.   Why  does  this  then  occur?  If  we  start  with  fully  infective  particles,  the  amount  of
infective particles drops in comparison to chimera and EV1 already after the first passage and is
under the detection limit already during the second passage.
Empty capsids are typically produced in varying amounts among picornavirus infections. They
sediment around 70 to 80 S in sucrose gradients and contain VP0, VP1 and VP3 (37-41), although
there  are  reports  of  FMDV  empty  capsids  that  contain  also  mature  VP2  and  VP4  (42).  One
explanation for these procapsids is that they form a reservoir of capsids where the genome may
possibly  be  inserted  (38,  40).  Despite  empty  capsids  being  common,  there  are  also  families  of
picornaviruses, such as human parechoviruses and especially Ljungan virus, that have not been
reported to produce empty particles (43). Ljungan virus shows substantial differences in the capsid
structure indicating that a different capsid form could have an effect on the genome encapsidation
and thus play a role in the production of empty particles (43).
There is some literature about the presence of defective infective particles (DIP) that naturally
interfere infection and replication of many viruses, including hepatitis B and C, influenza A virus,
Dengue virus, and poliovirus (44-47). DIPs show deletions of one or multiple genes and thus cannot
replicate alone, but during co-infection with fully infective viruses, will interfere with the outcome
of the virus infection (45). In our experiments, the TEM analysis and the metabolic labeling of CVB5
showed that our batches contained truly empty capsids without RNA content. Also, the fact that
increasing amounts of CVB5 empty viruses did not interfere with intact virions, argue against DIPS
present in our CVB5 population.
One possible reason for the observed low production of infective particles with CVB5 is to interfere
with the virus assembly step in the cytoplasm. How could that be affected by the structural proteins,
however, remains a puzzle. Could the assembly of new virions be disturbed during CVB5 infection?
Altogether, our data here shows that capsid proteins are determining the efficiency of infection for
the studied constructs, whereas 5´UTR and the non-structural proteins did not determine the switch
between cytolytic and more silent infection in A549 and RD cells, respectively. CVB5 infection leads
to  production  of  lower  amounts  of  infective  virions  in  relation  to  high  amount  of  empty  virus
particles, which delays the infection progress. If the empty capsids are removed, CVB5 infection will
lead to more efficient CPE but will soon start getting slower again, suggesting that the production
of empty particles in the expense of infective virions is a characteristic property of this CVB5 strain
in these type of cells, a feature previously reported for several different enteroviruses. Furthermore,
CVB5 behavior was different from CVB3, which uses the same cell surface receptors, further
demonstrating that the slowing down may be more linked to affecting assembly rather than viral
entry.
FIGURE LEGENDS
FIG 1. Production and characterization of EV1, chimera and CVB5 stocks in GMK cells. A) Schematic illustration of the
chimera containing the P1 region from EV1 and P2 and P3, including the 5’UTR from CVB5.  B) Graph showing the
infectivity (pfu/ml) and protein concentration of the produced virus stocks. C) SDS-PAGE analysis of virus stocks. Each
lane has 1 µg of virus.  Graphs showing the cell viability of infected A549 cells (D and E) and RD cells (F and G) detected
at 12h and 24h p.i.. In D and F, infections were done with equal protein concentration of 0,7 µg/ml, corresponding to
MOI 500 of EV1 and chimera and MOI 9 of CVB5. In E and G, infections were done with MOI 500.
FIG 2. Characterization of CVB3 and CVB5 infection in A549 and RD cells. A) Cell viability measurements during different
timepoints in A) A549 cells. B) Quantification showing the percentage of cells positive for capsid and dsRNA labelling in
A549 cells. C) cell viability in RD cells D) IF labeling quantifications in RD cells. Cell viability assay Infections were done
with MOI 65, with corresponding protein concentrations of 0,01 µg/ml for CVB3 and 1 µg/ml for CVB5. IF labeling
quantifications were made from three independent experiments with three replicates in each of them (total of 750 to
1350 cells / sample). Infections were done with MOI 65, with corresponding protein concentrations of 0,01 µg/ml for
CVB3 and 1 µg/ml for CVB5. Results are averages from four samples within one representative experiment with SEM.
Statistical significances are marked with ** < 0,01, *** < 0,001, **** < 0,0001.
FIG 3. CVB5 produced empty virus capsids in GMK cells. A) Graph showing the infectivity (pfu/ml) and protein
concentration of the CVB3 and CVB5 virus stocks produced in GMK cells. B) Structural characterization of the virus stocks
with the aid of TEM images and negative staining with representative magnifications. Scale bar 200 nm.
FIG 4. CVB5 infection kinetics with batch containing only intact viruses A) TEM image of negative stained differentially
produced CVB5 batch that mostly contained intact virus particles. B) Graph showing the cpm counts (% of total cpm)
after virus infections of GMK or A549 cells performed in the presence of radioactive methionine/cysteine. Cells were
infected with MOI 25. C) A549 or RD cells were infected with MOI 500 of EV1, chimera, CVB5 or CVB3 and cell viability
(ATP) was determined at 24 h p.i.. D) RT-qPCR from EV1, chimera and CVB5 infected A549 and RD cells. The cells were
infected with MOI 10, and after 1 h the medium was changed. The amount of positive sense RNA was determined from
the lysed cells at 2,8,24 and 48 h p.i. cDNA of chimera was used as a positive control. E) Confocal images showing dsRNA
and capsid distribution from A549 cells that were infected with EV1, chimera or CVB5, fixed and immunolabelled. 500
PFU/cell was first bound on ice for 1 h, after which excess virus was washed with 0.5% BSA in PBS. Infection was then
allowed to proceed at +37 ᵒC for 6 h.
FIG 5.  The infection efficiency of CVB5 is decreased in next generations which is not due to disturbance of empty
particles. A) Passage assay with CVB5 batch containing only intact particles at start. A549 cells were infected with EV1,
Chimera, CVB5 and CVB3 and CPE was monitored for four generations by passaging a similar amount of culture
supernatant to the next wells at 18 h intervals. Initial infection was done with MOI 500 for all constructs and the
medium was changed after 2 h. B) PFU/ml values of supernatants from the passage assay in A, were determined with
end-point dilution assay. C) CPE assay with intact CVB5 particles was carried out in the presence of increasing amount
of CVB5 empty particles or increasing amount of intact particles (MOI 43 (4.3 ng), MOI 21 (2.1 ng), MOI 6.5 (0.65 ng),
MOI 0.7 (0.07 ng)). Intact and empty particles were mixed together and added on A549 cells. The infection was
allowed to proceed for 20 h, after which the cell viability was determined by crystal violet staining.
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